The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 20, No. 44
November 22, 1991
NOTICES OF AVAILABILITY (RFAs AND RFPs)

ISO-ANTIGENIC TYPING OF MOUSE STRAINS (NCI-CM-27722-30) ........................................ 2
National Cancer Institute
INDEX: CANCER

CONSIGNEE FUNCTION AND QUARANTINE AGENT FOR NEW WORLD PRIMATES AND RELATED RESEARCH (NIH-RR-92-10) ... 2
National Institutes of Health
INDEX: NATIONAL INSTITUTES OF HEALTH

NCI SCIENCE ENRICHMENT PROGRAM (NCI-CN-25406-41) ................................................... 3
National Cancer Institute
INDEX: CANCER

GENE REGULATION OF RADIATION RESISTANCE (CA-92-03) .................................................. 3
National Cancer Institute
INDEX: CANCER

COORDINATING CENTER FOR INTERSTITIAL CYSTITIS DATA BASE (DK-92-04) ............................... 5
National Institute of Diabetes and Digestive and Kidney Diseases
INDEX: DIABETES, DIGESTIVE, KIDNEY DISEASES

REDUCTION IN MORTALITY AND MORBIDITY AMONG HEMODIALYSIS PATIENTS: PILOT STUDY (DK-92-10) ........ 7
National Institute of Diabetes and Digestive and Kidney Diseases
INDEX: DIABETES, DIGESTIVE, KIDNEY DISEASES

ONGOING PROGRAM ANNOUNCEMENTS

INSTITUTIONAL SHORT-TERM TRAINING FOR MINORITY STUDENTS PROGRAM (PA-92-17) ..................... 9
National Heart, Lung, and Blood Institute
INDEX: HEART, LUNG, BLOOD

ERRATUM

NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR THE TREATMENT OF OPPORTUNISTIC INFECTIONS ASSOCIATED WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AI-91-15) .......................................................... 10
National Institute of Allergy and Infectious Diseases
INDEX: ALLERGY, INFECTIOUS DISEASES

MINORITY DISSERTATION RESEARCH GRANTS IN AGING, 1992 (AG-91-14) ................................. 11
National Institute on Aging
INDEX: AGING
ISO-ANTIGENIC TYPING OF MOUSE STRAINS

RFP AVAILABLE: NCI-CM-27722-30

P.T. 34; K.W. 0745065, 0710125

National Cancer Institute

The Biological Testing Program (BTP), Developmental Therapeutics Program (DTP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI), National Institutes of Health (NIH), is seeking an organization that has the capabilities to perform reciprocal tail skin grafts between mice of various strain sublines and counterparts from the NIH colony. It is estimated that 6300 skin grafts involving 3,000 animals will be supplied at no charge to the contractor.

It is anticipated that one contract will be awarded for this effort, as a result of this Request for Proposals (RFP), for a period of 60 months. This RFP is a recompetition of the "Iso-Antigenic Typing of Mouse Strains" project being performed by Northwestern University. RFP No. NCI-CM-27733-30 will be available on or about December 9, 1991, by written request from:

Ms. Elsa B. Carlton
Contract Specialist, Research Contract Branch
Treatment Contract Section
National Cancer Institute
Executive Plaza South, Room 603
9000 Rockville Pike
Rockville, MD 20892

No collect calls will be accepted. Responses will be due by January 24, 1992.

CONSIGNEE FUNCTION AND QUARANTINE AGENT FOR NEW WORLD PRIMATES AND RELATED RESEARCH

RFP AVAILABLE: NIH-RR-92-10

P.T. 34; K.W. 1002002, 0780000

National Institutes of Health

The National Center for Research Resources (NCRR) has the mission of developing and supplying animal research resources for the intramural community at the National Institutes of Health (NIH) and assisting in the placement of research resources in extramural research institution programs. The purpose of the Consignee Function is to provide the services of a consignee and holding facility for New World primates imported into the United States from or with the Pan American Health Organization and foreign governments of Central and South America. Components of this requirement include, but are not limited to: receiving animals at an airport that accommodates direct international flights from source countries following clearance by U.S. Customs and inspection by the U.S. Department of Agriculture; temporarily housing animals; providing veterinary medical care, microbiological and parasitological screening, and tissue collections, as needed; and arranging the transshipment of animals to recipient research institutions. An additional requirement is to develop approaches and recommend methodologies to acquire new clinical, husbandry, and/or physiological data regarding the species entering the United States via the proposed contract. A three-year cost-reimbursement type contract is anticipated.

The solicitation is scheduled for release on or about November 29, 1991, and proposals will be due on or about December 30, 1991. All responsible sources may submit a proposal that will be considered.

Requests for the Request for Proposals must be directed to:

Silver C. Jones
Contract Specialist, Research Contracts Branch
Division of Contracts and Grants
National Institutes of Health
Building 31, Room 1844
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 496-4487
NCI SCIENCE ENRICHMENT PROGRAM

RFP AVAILABLE: NCI-CN-25406-41

P.T. 34, FF; K.W. 0502000, 0710030

National Cancer Institute

The National Cancer Institute (NCI), Division of Cancer Prevention and Control, Cancer Control Science Program, is interested in soliciting proposals for conducting regional, summer resident "Science Enrichment Programs" for incoming tenth grade underrepresented minority and underserved youth who have a demonstrated interest in science and/or mathematics. The goals of this program are: (1) to encourage underrepresented minority and underserved youth to pursue professional and careers in science and research, and (2) to broaden and enrich students' science, research and sociocultural backgrounds. High schools collaborating with colleges and/or universities, colleges, universities, as well as cancer centers and schools of public health are among the eligible offerors. It is anticipated that several awards will be made for a two-year period (with a two-year option clause), to be incrementally funded as a cost-reimbursement type contract. Two pre-proposal conferences are anticipated, one in Bethesda, Maryland. The Request for Proposals (RFP) will specify the location, dates, and times for each conference.

Date of issue for this RFP will be approximately November 22, 1991, with a closing date for proposals of January 10, 1992. Anticipated award date is mid May 1992. This Resident Program is to be implemented during the Summer of 1992.

Copies of the RFP may be obtained by sending a written request that references RFP No. NCI-CN-25406-41 to:

Susan K. Hoffman, Contracting Officer
Research Contracts Branch, PCCS
National Cancer Institute
Executive Plaza South, Room 635
9000 Rockville Pike
Bethesda, MD 20892
Telephone: (301) 496-8603

GENE REGULATION OF RADIATION RESISTANCE

RFA AVAILABLE: CA-92-03

P.T. 34; K.W. 0765015, 1002058, 0745062

National Cancer Institute

Letter of Intent Receipt Date: January 3, 1992
Application Receipt Date: March 13, 1992

PURPOSE

The NCI announces the availability of a Request For Application (RFA) for tightly focused studies that investigate the molecular/genetic mechanisms responsible for the inherent radioresistance of human tumor cells.

HEALTHY PEOPLE 2000

The Public Health Service (PHS), is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Gene Regulation of Radiation Resistance, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign, for-profit and nonprofit, public and private organizations, such as universities, colleges, hospitals, laboratories, units of State or local governments, and eligible agencies of the Federal Government. Although NCI-funded Cooperative Groups are ineligible to apply, individual institutions or consortia of the Cooperative Groups may apply through their own institutions. Domestic applications may include international components. Applications from minority individuals and women are encouraged.

MECHANISM OF SUPPORT

This RFA will use the National Institutes of Health (NIH) individual research project grant (R01) funding mechanism. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. Except as otherwise stated in this RFA, awards will be administered under PHS grants.
policy as stated in the Public Health Service Grants Policy Statement. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed by a Division of Research Grants (DRG) study section. If the NCI determines that there is a sufficient continuing program need, the NCI may announce a request for competitive continuation applications. The total project period for applications submitted in response to the present RFA may not exceed three years. The anticipated award date will be December 1, 1992.

Funds Available

Approximately $1,000,000 in total costs per year for three years will be committed to specifically fund applications submitted in response to this RFA. This funding level is dependant on the receipt of a sufficient number of applications of high scientific merit. NCI plans to make multiple (four to five) awards for project periods up to three years. The total project period for applications submitted in response to the present RFA may not exceed three years. Although this program is provided for in the financial plans of the NCI, the award of grants pursuant to this RFA is also contingent upon the continuing availability of funds for this purpose.

Research Objectives

The purpose of this RFA is to stimulate research directed towards identifying and characterizing the role that molecular/genetic processes play in the inherent radioresistance observed in some solid human tumor cells that often exceeds that of the normal cells. Studies must be directed toward investigating the various molecular/genetic events that occur following radiation-induced damage and determining how they relate to radiation resistance. These studies may include, but not be limited to, various facets of gene induction and expression, i.e., regional transduction pathways, second messenger pathways, oncogene products, growth factors, and molecular and/or biochemical factors.

By better understanding the radiation resistance associated with human tumor cells, it may be possible to modulate those mechanisms identified as playing significant roles and thereby significantly improve the clinical effect of radiation therapy. Additionally, important molecular and cellular prognostic factors for survival or recurrence of malignancy in patients treated with radiotherapy may be identified from the proposed studies.

Study Population

It is NIH policy that women and minorities must be included in clinical study populations unless there is a good reason to exclude them, and the study design must seek to identify any pertinent gender or minority population differences.

Special Instructions for Inclusion of Women and Minorities in Clinical Research Studies

For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review.

Application Procedures

Copies of the RFA are available from the Program Director's office listed below. The United States Public Health Service research grant application form PHS 398 (revised 10/88, reprinted 9/89) must be used in applying for these grants. Grant application forms are usually available at most institutional business offices and from the NIH Office of Grant Inquiries, Division of Research Grants, National Institutes of Health, Room 449, Westwood Building, 5333 Westbard Avenue, Bethesda, MD 20892; telephone (301) 496-7441. The receipt date for applications is March 13, 1992.

Inquiries

Written and telephone inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Thomas A. Strike, Ph.D.
Radiation Research Program
National Cancer Institute
Executive Plaza North, Suite 800
Bethesda, MD 20892
Telephone: (301) 496-9360

DIRECT INQUIRIES REGARDING FISCAL MATTERS TO:

Ms. Carolyn Mason
Grants Administration Branch
National Cancer Institute
6120 Executive Boulevard, Suite 243
Bethesda, MD 20852
Telephone: (301) 496-7800 Ext. 59

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance No. 93.405, (Clinical Treatment Research). Awards are made under authorization of the Public Health Service Act, Title IV, Part A. (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285), and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

COORDINATING CENTER FOR INTERSTITIAL CYSTITIS DATA BASE

RFA AVAILABLE: DK-92-04

P.T. 34; K.W. 0755018, 0413001, 0785055

National Institute of Diabetes and Digestive and Kidney Diseases

Letter of Intent Receipt Date: January 10, 1992
Application Receipt Date: February 18, 1992

PURPOSE

The Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), announces the availability of a Request for Applications (RFA) for a central data coordinating center that will participate with the Clinical Centers in the development of a data base for interstitial cystitis. The data coordinating center will collect, maintain and analyze data and assess patient samples provided by the Clinical Centers. The primary objectives of this investigation are: (1) to establish and maintain a data base of uniformly and accurately collected information, including results of the analysis of clinical samples, from patients with interstitial cystitis; (2) to study the natural history of this disorder; and (3) to make available the data base and patient samples for other interested investigators to conduct epidemiological and clinical studies. The assistance mechanism used to support this study is the cooperative agreement.

ELIGIBILITY

Domestic universities, medical colleges, hospitals, and other public and private research institutions, including State and local government units, are eligible. Applications from foreign institutions will not be considered. Applications from minority investigators and women are encouraged.

RESEARCH OBJECTIVES

The primary purpose of this program is to develop an interstitial cystitis data base through the collection and analysis of information and clinical samples from patients with the disorder. The NIDDK will support the function of a separate Data Coordinating Center (DCC) for the study, that will have primary responsibility for collecting, editing, storing, and analyzing data and assessing patient samples provided by the Clinical Centers. The DCC must be prepared to design a data and patient specimen collection system, assure quality control and provide appropriate detailed data reports to the Steering Committee and to the External Advisory Committee at regular intervals. The DCC will be responsible for the logistics, planning, and funding of the meetings of these committees. The DCC will be expected to provide appropriate biostatistics; data management; handling of patient samples, interpretation, and distribution; and study-wide coordination expertise. Applicants must provide a detailed description of prior experience in multicenter studies and identify in the application a collaborating Central Laboratory (or laboratories) for testing patient samples, including bladder biopsies. The Central Laboratory will be responsible for establishing procedures for collection of patient samples, including bladder biopsies, serum and urine samples, testing these samples and reporting results to the DCC and Clinical Centers, maintaining laboratory quality control procedures, and providing periodic training in specimen collection and transport procedures.

The study will consist of three sequential phases: Phase I: Development of Protocol (six to eight months); Phase II: Recruitment of Study Sample and Interim Data Analysis (48 months); and Phase III: Final Data Analysis and Reporting (six months). Phase I will be completed by the study Steering Committee prior to the involvement of the DCC.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity for setting priority areas. This Request for Applications (RFA), Data Coordinating Center for the Interstitial Cystitis Data Base, is related to the priority area of diabetes and chronic disabling diseases. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00473-1) or "Healthy People 2000" Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238).

MECHANISM OF SUPPORT

The administrative and funding mechanism to be used to undertake this program will be the cooperative agreement (U01). It is anticipated that one award of approximately $250,000 total costs for the first year will be made under this RFA. Funding is expected to begin in Fiscal Year 1992; total support for the project will be for approximately five years.

TERMS AND CONDITIONS OF AWARD

The tasks and activities in which awardees will have substantial responsibilities include data and patient sample collection, quality control, final data analysis and interpretation, control of publications, the logistics and funding of Steering Committee meetings, and collaboration with Clinical Center awardees. All awardees will have primary access and rights to data and samples collected in this study.

REVIEW PROCEDURES AND CRITERIA

Upon receipt, applications will be reviewed by NIDDK staff for responsiveness to the objectives of this RFA. Those applications judged to be responsive will be further evaluated for scientific and technical merit by an appropriate peer review group convened by the Division of Extramural Activities, NIDDK, using criteria given in the RFA. Subsequent review will be by the National Diabetes and Digestive and Kidney Diseases Advisory Council.

SEMINAR FOR PROSPECTIVE APPLICANTS

A one-day seminar for prospective applicants will be held approximately one month after the publication of this announcement. The purpose of this seminar is to give background information on the clinical aspects of interstitial cystitis, an update on the activities of the Clinical Centers, and to respond to any questions about the preparation of an application. Interested persons may contact the Urology Program Director, Dr. Leroy M. Nyberg, for further information (see below).

APPLICATION PROCEDURES

Letter of Intent -- Prospective applicants are asked but not required to submit a letter of intent to apply to the RFA. This letter is to include the name, telephone number and mailing address of the Principal Investigator, the names of other key personnel, the name of the applicant institution and the number and title of this RFA. Letters of intent to apply to this RFA are to be received no later than January 10, 1992 and are to be addressed to:

Dr. Robert D. Hammond
Chief, Review Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 603
Bethesda, MD 20892

Format for Applications -- Submit applications on form PHS 398 (revised 10/88, reprinted 9/89), the application form for the traditional NIH research project grant. Copies of this form are available in the applicant institution's office of sponsored research and may be obtained from Office of Grants Inquiries, Division of Research Grants, Westwood Building, Room 449, National Institutes of Health, Bethesda, MD 20892, telephone (301) 496-7447. Applications must be received by February 18, 1992. An application not received by this date will be considered ineligible and returned to the applicant.

INQUIRIES

It is essential that prospective applicants obtain a copy of the RFA before preparing an application. Requests may be directed to:

REDUCTION IN MORTALITY AND MORBIDITY AMONG HEMODIALYSIS PATIENTS: PILOT STUDY

RFA AVAILABLE: DK-92-10

P.T. 34; K.W. 0745025, 0715075, 0710095, 0755015

National Institute of Diabetes and Digestive and Kidney Diseases

Letter of Intent Receipt Date: February 7, 1992
Applications Receipt Date: March 13, 1992

PURPOSE

The Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces the availability of a Request for Applications (RFA) for cooperative agreements to carry out a pilot clinical trial directed toward reducing overall mortality and morbidity among the hemodialysis patient population. Areas of investigation may include an evaluation of different modes of dialysis with respect to patient outcome. For instance, one objective of the clinical trial could be to assess the effect of high-flux hemodialysis on mortality and morbidity. The study may include the design of a comprehensive and uniform program of high quality medical care for control of blood pressure, lipid levels, and diabetes, as well as appropriate nutrition counseling and management of vascular access.

ELIGIBILITY

Domestic universities, medical colleges, hospitals, and other public and private research institutions, including State and local government units, are eligible. Applications from minority investigators and women are encouraged. Applications from foreign institutions will not be considered since only a small number of centers will be selected to participate in this program.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Reduction in Mortality and Morbidity Among Hemodialysis Patients: Pilot Study, is related to the priority area of diabetes and chronic disabling diseases. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00473-1) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238).

RESEARCH OBJECTIVES

The primary purpose of this RFA is to initiate a collaborative pilot study of hemodialysis therapy to investigate the modes and practices of hemodialysis therapy for the purpose of reducing mortality and morbidity among patients with end-stage renal disease. The pilot study will test the feasibility of conducting a full-scale randomized clinical trial in an adequately sized patient population. Patient factors such as elevated blood pressure and lipid levels, diabetes, vascular access site, as well as nutrition, may be managed in a uniform manner among all randomized patients.
MECHANISM OF SUPPORT

The assistance mechanism used to support the study is the cooperative agreement (U01), which is similar to the traditional NIH research grant. The cooperative agreement mechanism is an award instrument establishing an assistance relationship between NIH and a recipient, in which substantial programmatic involvement is anticipated between NIH and the recipient during performance of the contemplated activity.

FUNDS AVAILABLE

It is anticipated that six awards (four clinical centers, one Data Coordinating Center, and one Intervention Coordinating Center) will be made under this RFA for a total of approximately $1 million (including direct and indirect costs) during the first year. The funding level for the Clinical Centers will be approximately $100,000 in total cost for each Clinical Center, approximately $300,000 in total costs for the Data Coordinating Center, and approximately $300,000 in total costs for the Intervention Coordinating Center per year. Funding is expected to begin in September 1992; total support for the project will be for 30 months.

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included or adequately represented in the study populations for clinical studies, a specific justification for this exclusion or inadequate representation must be provided. Applicants without such documentation will not be accepted for review.

REVIEW CONSIDERATIONS

Upon receipt, applications will be reviewed by NIDDK staff for responsiveness to the objectives of this RFA. If an application is judged unresponsive, the applicant will be contacted and given the opportunity to withdraw the application, or to have it considered for the investigator-initiated research grant program. If the number of applications is large compared to the number of awards to be made, the NIDDK will conduct a preliminary scientific peer review and withdraw applications from further competition if they are judged to be non-competitive for award. The NIDDK will notify the applicant and institutional official of this action.

Those applications judged to be both responsive and competitive and will be evaluated further for scientific and technical merit by an appropriate peer review group convened by the Division of Extramural Activities, NIDDK. Subsequent review will be by the National Diabetes and Digestive and Kidney Diseases Advisory Council.

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 10/88, reprinted 9/89) must be used in applying for these grants. These forms are available at most institutional business offices and from the Office of Grants Inquiries, Division of Research Grants, NIH, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone (301) 496-7441.

INQUIRIES

It is essential that potential applicants and other interested individuals contact the Clinical Trials Program Director, NIDDK, to obtain the RFA before preparing an application. Written and telephone inquiries are encouraged, and may be directed to:

John W. Kusek, Ph.D.
Clinical Trials Program Director
Division of Kidney, Urologic and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 3A04C
5333 Westbard Avenue
Bethesda, MD 20892
Telephone: (301) 496-7133
FAX: (301) 402-0223

For fiscal and administrative matters, contact:

Nancy C. Dixon
Supervisory Grants Management Specialist
Grants Management Branch, DEA
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 649B
Bethesda, MD 20892
Telephone: (301) 496-7467

AUTHORITY AND REGULATIONS

These programs are described in the Catalog of Federal Domestic Assistance No. 93.849 Kidney, Urologic and Hematologic Diseases Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended: 42 USC 241) and administered under PHS Grants Policies and
Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental requirements of Executive Order 12372 or Health Systems Agency review.

ONGOING PROGRAM ANNOUNCEMENTS

INSTITUTIONAL SHORT-TERM TRAINING FOR MINORITY STUDENTS PROGRAM

PA AVAILABLE: PA-92-17

P.T. 44, FF; K.W. 0720005, 0710030, 0715040, 0715165, 0715032

National Heart, Lung, and Blood Institute

Letter of Intent Receipt Date: January 6, 1992
Application Receipt Date: February 14, 1992

The National Heart, Lung, and Blood Institute (NHLBI) announces the availability of the second competition for the Institutional Short-Term Training for Minority Students Program. Copies of the Program Guidelines are currently available from staff of the NHLBI (listed below).

OBJECTIVES OF THE AWARD

1. To bolster the exposure of minority undergraduate students, graduate students, and students in health professional schools to opportunities inherent in research careers in areas relevant to cardiovascular, pulmonary, and hematologic* diseases.

2. To bolster the already short supply of minority investigators and attract highly qualified minority students into biomedical and behavioral research careers.

* For the purposes of this award, the term "hematologic" covers research on thrombosis and hemostasis, immunohematology, blood cell disorders, sickle cell disease, blood resources including blood component and derivative therapy, blood substitutes and blood resource management, aspects of AIDS-products in AIDS prevention and treatment, AIDS-related bone marrow and hematologic disorders, and the lymphocirculatory system.

ELIGIBILITY

Domestic institutions and organizations, including minority institutions, engaged in health-related research in areas pertaining to heart, lung, and blood disorders may apply for grants. These grants will support short-term research training experiences of two to three months' duration for minority undergraduate students, minority students in health professional schools, and minority graduate students. Trainees appointed to the program need not be from the grantee institution, but may include a number of minority students from other institutions, schools, colleges, and universities. Special attention must be given to the recruitment of individuals from minority groups that are underrepresented nationally in the biomedical and behavioral sciences, i.e., African American, Hispanic Americans, Native Americans, Alaskan Americans, and Pacific Islanders.

MECHANISM OF SUPPORT

The mechanism of support is the institutional National Research Service Award for Short-term Research Training (135) for students in health professional schools. Institutions may request up to five years of support for short-term training programs for at least four and not more than 24 trainees per year. The stipend level for trainees is $733 per month. Stipends may be supplemented from non-Federal funds. Training-related expenses up to $125 per month per trainee may be requested. In addition, up to $700 per trainee may be requested to cover domestic travel to and from the training site. Trainee tuition and fees, where necessary to the research training, must be covered by the training-related expenses. Indirect costs will be awarded based on eight percent of total direct costs with no exclusions from the base for training-related expenses.

REVIEW OF APPLICATIONS

All applications responding to this announcement will be reviewed for scientific and technical merit by the Research Training Review Committee of the Division of Extramural Affairs, NHLBI, followed by a second level review by the National Heart, Lung, and Blood Advisory Council.

LETTER OF INTENT

Each prospective applicant is requested to forward a letter of intent that includes a descriptive title, the name and address of the Program Director, the names and key investigators, and any other participating institutions. Such letters are requested for the purposes of obtaining an indication of the number and scope of the applications to be reviewed. A letter of intent is not binding, is not a requirement of submission, and does not enter into the review of the application. The letter of intent is requested by January 6, 1992, and is to be addressed to:

Scientific Review Administrator
Research Training Review Committee
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
National Institutes of Health
Westwood Building, Room 550
Bethesda, MD 20892

TIMETABLE

Letter of intent (optional): January 6, 1992
Application receipt date: February 14, 1992
Scientific review: May/June 1992
Advisory Council review: September 10-11, 1992
Award date: September 30, 1992

Copies of the Program Guidelines for this program may be obtained from any of the following:

John Fakunding, Ph.D.
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
Federal Building, Room 3C04
Bethesda, MD 20892
Telephone: (301) 496-1724

Fann Harding, Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Federal Building, Room 5A08
Bethesda, MD 20892
Telephone: (301) 496-1817

Mary Reilly, M.S.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
Westwood Building, Room 640A
Bethesda, MD 20892
Telephone: (301) 496-7668

For fiscal and administrative matters contact:

Grants Operations Branch
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
National Institutes of Health
Westwood Building, Room 4A15C
Bethesda, MD 20892
Telephone: (301) 496-7255

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance Numbers 93.837, 93.838, and 93.839. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grants policies and Federal Regulations at 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

ERRATUM

NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR THE TREATMENT OF OPPORTUNISTIC INFECTIONS ASSOCIATED WITH ACQUIRED IMMUNODEFICIENCY SYNDROME

RFA: AI-91-15
P.T. 34; K.W. 0715008, 0715125, 0755025, 0710100
National Institute of Allergy and Infectious Diseases

Letter of Intent Receipt Date (revised): November 22, 1991
Application Receipt Date: January 16, 1992

The National Cooperative Drug Discovery Groups for the Treatment of Opportunistic Infections Associated with Acquired Immunodeficiency Syndrome (NCDDG-AIDS) Request for Applications (RFA) (NIH Guide for Grants and Contracts - Vol. 20, No. 39, October 18, 1991) states that research focusing on anti-folates or sulphonamides will not be supported under this RFA. This statement is amended to read: With the exception of investigations involving Cryptosporidium parvum, research focusing on anti-folates or sulphonamides will not be supported under this RFA.

In an effort to provide potential applicants with additional time to prepare brief descriptions of proposed research, the receipt date for the requested letter of intent is extended to November 22, 1991.

Inquiries concerning this RFA may be directed to:

Barbara Laughon, Ph.D.
Targeted Drug Discovery Section
Developmental Therapeutics Branch
Division of AIDS
National Institute of Allergy and Infectious Diseases
6003 Executive Blvd.
Bethesda, MD 20892
Telephone: (301) 496-8197

MINORITY DISSERTATION RESEARCH GRANTS IN AGING, 1992

RFA: AG-91-14
P.T. 34, FF; K.W. 0710010, 0720005
National Institute on Aging
Application Receipt Date: March 11, 1992 (revised)

This Request for Applications (RFA) was announced in the NIH Guide to Grants and Contracts, Vol. 20, No. 37, October 4, 1991. The application receipt date has been extended from December 20, 1991 to March 11, 1992.

Small grants (R03) to support doctoral dissertation research will be available in 1992 for underrepresented minorities. Grant support is designed to aid the research of new minority investigators and to encourage individuals from a variety of academic disciplines and programs to study problems in aging. Specific research topics should be discussed with NIA. The interests of the programs are given in the RFA, which is available from:

Phyllis B. Eveleth, Ph.D.
Deputy Associate Director and Training Officer
Office of Extramural Affairs
National Institute on Aging
Gateway Building, Suite 218
Bethesda, MD 20892
Telephone: (301) 496-9322

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD BUILDING IS:**

5333 Westbard Avenue
Bethesda, MD 20816

HAPPY THANKSGIVING FROM NIH